Compare General Dynamics Corporation (GD) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Dynamics Corporation vs Natera Inc. Common Stock — how do they compare? General Dynamics Corporation trades at $336.76 (market cap $89.94B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: General Dynamics Corporation is the larger of the two by market cap, and General Dynamics Corporation pays a 1.91% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Dynamics Corporation for 86 Days and Natera Inc. Common Stock for 0 Days on average.
| GD | NTRA | |
|---|---|---|
Market Cap | $89.94B | $57.03B |
Volume | 1,284,020 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $395.97 | $425.64 |
52-Week Low | $312.53 | $179.42 |
Typical Hold Time | 86 Days | 0 Days |
Enterprise Value | $95.08B | $56.18B |
Dividend Yield | 1.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Dynamics (GD) trades at $334.66, down 0.24% with bearish technical signals despite strong fundamentals. The defense contractor shows robust revenue growth, increasing from $47.7B in 2024 to $52.5B in 2025, with consistent earnings beats. Analyst consensus remains bullish with a $414.57 price target, supported by strong Pentagon spending and dividend stability.
GD presents a compelling value opportunity with reasonable valuation multiples (P/E 20.27) and strong cash flow generation. Key risks include defense budget volatility and execution challenges, but the company's record backlog and dividend champion status provide downside protection. Upside potential exists if technical resistance at $337 is breached.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
